NY-EMENDO-BIO
17.5.2022 22:17:09 CEST | Business Wire | Press release
Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.
Emendo presented pre-clinical data for the treatment of ELANE -related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo , showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.
“ELANE -based Severe Congenital Neutropenia, Emendo’s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,” said David Baram, Ph.D., President & CEO of Emendo Biotherapeutics. “We are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year’s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.”
Senior members of the Emendo Biotherapeutics R&D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research & Development Rafi Emmanuel, Ph.D. presented Emendo’s research on-site at the conference.
Session Presentation
Title: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia
Session Title: Gene Therapy for Immunologic Diseases
Session Date/Time: Tuesday May 17, 2022 3:45 PM - 5:30 PM
Presentation Time: 3:45pm - 4:00pm
Room: Room 202
Final abstract number: 482
Poster Presentations
Title: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy
Session Title: Cancer - Targeted Gene and Cell Therapy I
Session Date/Time: Monday May 16, 2022 5:30 PM - 6:30 PM
Poster Board Number: M-215
Room: Hall D
Final abstract number: 334
Title: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date/Time: Wednesday May 18, 2022 5:30 PM - 6:30 PM
Poster Board Number: W-125
Room: Hall D
Final abstract number: 999
Title: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification
Session Title: Gene Targeting and Gene Correction II
Session Date/Time: Tuesday May 17, 2022 5:30 PM - 6:30 PM
Poster Board Number: Tu-61
Room: Hall D
Final abstract number: 556
About Emendo Biotherapeutics
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit www.emendobio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grafana Labs Charts the Path to Agentic Operations with Watchers, Pages, and Agent Observability at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Grafana Labs delivers AI for observability and observability for AI: always-on agents to operate systems, and OpenTelemetry-native visibility into the agents you ship Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that move Grafana Cloud towards agentic operations, including the general availability of Agent Observability with OpenTelemetry support and of Assistant Watchers, and previews of Grafana Pages and Grafana Managed Sandboxes. As AI moves into production, teams face two connected challenges: using agents to operate their systems and understanding the behavior of the agents themselves. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum company, 68% of the 300 IT and engineering leaders surveyed have moved AI for observability past investigation into pilots or production. But confidence depends on the task and readiness varies: 85% report comfort with r
Grafana Labs Brings Faster Full-text Search and Smarter Data Optimization to Grafana Cloud at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Adaptive Logs Archive lets teams keep more logs for less, and faster queries for rare values in Grafana Cloud Logs help them, and their agents, find what matters in seconds Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that help teams manage their telemetry in the AI era, finding the right log line in seconds and keeping only the telemetry worth paying for as AI workloads scale. Major query performance enhancements to Grafana Cloud Logs, built on technology from the company's Logline acquisition, are now generally available, and Adaptive Logs Archive is in public preview. AI is massively increasing telemetry volumes. Coding agents are turning everyone into a developer, so more software is being built, faster, and all of it needs to be watched. The agents add to the load too, since every agent call and tool call emits its own telemetry. Left alone, observability costs grow with every new workload, which makes
Nissan Technical Centre Europe Adopts Sonatus Fastlane™ Platform to Accelerate Vehicle Test and Validation20.10.2026 18:37:00 CEST | Press release
Event-driven data collection and AI-powered root-cause analysis to become standard practice for new NTCE vehicle programs; Proven to cut investigation time from two weeks to two days Following a successful proof of concept and ongoing engineering development over the past 12 months, Nissan Technical Centre Europe (NTCE), Nissan’s primary R&D hub for its global regions, is expanding its use of the Sonatus® Fastlane™ Platform across its pre-start-of-production (SOP) validation workflow. The platform’s event-driven data collection and root-cause analysis have reduced the time NTCE engineers spend investigating vehicle software issues from two weeks to two days. NTCE plans to make the platform a standard part of validating future vehicle programs, including upcoming models such as the Nissan JUKE. With the Fastlane Platform, engineers have the data they need from the moment a fault occurs. Teams deploy targeted data-collection policies from the cloud, and capture begins automatically when
FlightSafety International and Honda Aircraft Company Partner to Offer New Course to HA-420 Pilots20.10.2026 18:00:00 CEST | Press release
Expanded collaboration brings advanced runway safety training to HondaJet pilots FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an expansion of its longstanding partnership with Honda Aircraft Company to provide a new Runway Operations Mastery course for HA-420 Elite and Elite II pilots. Developed in collaboration with Honda Aircraft Company, the immersive training course focuses on strengthening pilot proficiency to support safer operations. The new voluntary offering reflects the companies’ shared commitment to advancing aviation safety through specialized training. “For more than 75 years, FlightSafety’s mission has been to advance aviation safety through training that addresses real-world challenges pilots face,” said Ben Carter, Executive Vice President, Learning Center Operations, FlightSafety International. “This new course reflects our ongoing commitment to working with our OEM partners to deliver special
TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform20.10.2026 17:00:00 CEST | Press release
The Cessna Grand Caravan EX Veris provides a high-fidelity, cost-effective solution for pilot development and expands training opportunities for one of the world’s most widely operated utility aircraft TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced today the introduction of its Cessna Grand Caravan EX Veris Virtual Reality Flight Training Device (FTD), expanding the Veris product line to support one of the aviation industry's most versatile and widely utilized aircraft platforms. The announcement marks the first Caravan-configured training device offered within TRU Simulation's portfolio and reflects the company's continued investment in immersive aviation training technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020834162/en/ TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform "The Veris p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom